C5 and membranous glomerulonephritis: Additionally, investigational drugs targeting C5 such as Crovalimab (NCT04861259) and gefurulimab (NCT06208488) (C5 inhibitors), Cemdisiran (a siRNA targeting the C5 mRNA transcript- NCT03841448, NCT03999840) are in various stages of clinical trials in several glomerular diseases, including an atypical HUS, IgA nephropathy, lupus nephritis, membranous nephropathy and focal segmental glomerulosclerosis (NCT05314231).